Physiomics plc announced that it has been awarded a new contract by an existing, large client. The project involves the use of proprietary Virtual Tumour platform to model the client's targeted oncology agents in combination with other modalities to help inform dose and scheduling decisions. The value of the contract is £186,000 and it is anticipated that it will be completed over the course of the current calendar year.

This project and associated contract award is the second of the two referred to in the Company's trading update on 3 May 2024 and now means that the Company will be going into its next financial year ending 30 June 2025 with committed revenues of over £0.5 million.